Table 3.
Lymphovascular space invasion and survival of women with ovarian cancer
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Case number | HR (95% CI) | P | HR (95% CI) | P | |
| Training set cohort | |||||
| Progression-free survival | |||||
| High-grade serous carcinoma (yes vs. no) | 93 vs. 34 | 2.20 (1.27–3.83) | 0.004 | 0.19 | |
| FIGO stage (per stage) | 11 vs. 11 vs. 90 vs. 15 | 2.30 (1.60–3.30) | <0.001 | 1.95 (1.26–3.01) | 0.003 |
| LVSI (yes vs. no) | 101 vs. 26 | 3.36 (1.67–6.74) | <0.001 | 2.06 (1.01–4.24) | 0.048 |
| Overall survival | |||||
| FIGO stage (per stage) | 11 vs. 11 vs. 90 vs. 15 | 2.29 (1.45–3.60) | 0.013 | 2.17 (1.31–3.60) | 0.003 |
| LVSI (yes vs. no) | 101 vs. 26 | 3.29 (1.32–8.24) | 0.007 | 0.1 | |
| Validation cohort | |||||
| Progression-free survival | |||||
| High-grade serous carcinoma (yes vs. no) | 28 vs. 61 | 3.77 (1.90–7.46) | <0.001 | 0.26 | |
| FIGO stage (per stage) | 37 vs. 20 vs. 31 vs. 5 | 3.05 (2.09–4.44) | <0.001 | 2.57 (1.59–4.00) | <0.001 |
| LVSI (yes vs. no) | 48 vs. 45 | 3.65 (1.72–7.78) | 0.003 | 1.99 (0.90–4.20) | 0.09 |
| Overall survival | |||||
| High-grade serous carcinoma (yes vs. no) | 28 vs. 61 | 2.84 (1.27–6.34) | 0.008 | 0.75 | |
| FIGO stage (per stage) | 37 vs. 20 vs. 31 vs. 5 | 2.54 (1.64–3.92) | <0.001 | 2.60 (1.48–4.57) | 0.001 |
| LVSI (yes vs. no) | 48 vs. 45 | 3.35 (1.34–8.40) | 0.006 | 0.18 | |
Cox proportional hazard regression test. Examined all the collected variables and only significant variables are listed. HR, hazard ratio; 95% CI, 95% confidence interval; FIGO, the International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion.